Presentation description

Invasive mucinous adenocarcinoma (IMA) is a rare subtype of NSCLC primarily driven by KRAS mutations, leading to uncontrolled cell growth. IMA remains resistant to standard treatments, and few clinically employed therapies specifically target KRAS-driven IMA. This study investigates novel targeted therapies using both in-vivo and in-vitro models to assess their efficacy, aiming to identify more effective treatment options in an effort to improve patient outcomes.